The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Open accessAbstract
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four doses of ipilimumab (at 3 mg per kilogram) every 3 weeks. Primary end points were progression-free and overall survival. RESULTS: The estimated 6-month progression-free-survival rates were 47.3% for pembrolizumab every 2 weeks, 46.4% for pembrolizumab every 3 weeks, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens versus ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, respectively). Estimated 12-month survival rates were 74.1%, 68.4%, and 58.2%, respectively (hazard ratio for death for pembrolizumab every 2 weeks, 0.63; 95% CI, 0.47 to 0.83; P=0.0005; hazard ratio for pembrolizumab every 3 weeks, 0.69; 95% CI, 0.52 to 0.90; P=0.0036). The response rate was improved with pembrolizumab administered every 2 weeks (33.7%) and every 3 weeks (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons). Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, respectively, after a median follow-up of 7.9 months. Efficacy was similar in the two pembrolizumab groups. Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%). CONCLUSIONS: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“however responses to these therapies are often heterogeneous and not durable (1–3).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with anti-PD-1 and anti-PD-1/CTLA-4 combination therapy emerging as most effective [3, 4].”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There were 16 responders (from here on, referred to as R) and 26 nonresponders (NR), yielding a response rate of 38%, which is in line with published clinical data of anti–PD-1 therapy in metastatic melanoma patients (5, 6).”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [6]
In the citing paper
“Severe adverse reactions include severe diarrhea, colitis, increased alanine aminotransferase levels, inflammation pneumonitis, and interstitial nephritis (67, 73, 99).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [73]
In the citing paper
“In the subsequent phase III clinical trial, more than 30% of patients with advanced melanoma achieved an objective response following pembrolizumab monotherapy compared with 12% of patients treated with ipilimumab alone (58).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [58]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [2]
In the citing paper
“In order to limit the risk of severe immune-related adverse events (irAEs) or exacerbation of underlying autoimmune or inflammatory disease, patients with preexisting autoimmune disorders (ADs) or those receiving systemic immunosuppression for organ transplantation have been universally excluded from clinical trials.3,4”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [4]
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Research works printed but not linked: 2
- Ribas A, 2014, Pigment Cell Melanoma Res, 27, 1223
- Robert C, 2014, Ann Oncol, 25, LBA34
Cited by
Sorted by citations
Items 801–900 of 1,039
Grassadonia, A., Sperduti, I., Vici, P., Iezzi, L., Brocco, D., Gamucci, T., Pizzuti, L., Maugeri‐Saccà, M., Marchetti, P., Cognetti, G., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120542 · Cited by 112
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Cadranel, J. L., Canellas, A., Matton, L., Darrason, M., Parrot, A., Naccache, J., Lavolé, A., Ruppert, A.-M., & Fallet, V. (2019) · European Respiratory Review · doi:10.1183/16000617.0058-2019 · Cited by 113
Gastrointestinal side effects of cancer treatments
O’Reilly, M., Mellotte, G. S., Ryan, B. M., & O’Connor, A. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320970354 · Cited by 112
Wongvibulsin, S., Pahalyants, V., Kalinich, M., Murphy, W., Yu, K., Wang, F., Chen, S. T., Reynolds, K. L., Kwatra, S. G., & Semenov, Y. R. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.094 · Cited by 112
Jurj, A. M., Ionescu, C., Berindan‐Neagoe, I., & Braicu, C. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02484-1 · Cited by 113
Towards a consensus definition of immune exclusion in cancer
Tiwari, A., Oravecz, T., Dillon, L. A. L., Italiano, A., Audoly, L., Fridman, W. H., & Clifton, G. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1084887 · Cited by 117
Madore, J., Strbenac, D., Vilain, R. E., Menzies, A. M., Yang, J. Y. H., Thompson, J. F., Long, G. V., Mann, G. J., Scolyer, R. A., & Wilmott, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1714 · Cited by 111
Self-citationThe use of pembrolizumab for the treatment of metastatic uveal melanoma
Kottschade, L. A., McWilliams, R. R., Markovic, S. N., Block, M. S., Villasboas, J. C., Pham, A., Esplin, B. L., & Dronca, R. S. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000242 · Cited by 111
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
Bartee, M. Y., Dunlap, K. M., & Bartee, E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1638 · Cited by 111
Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
Bilir, C., & Sarısözen, C. (2017) · Journal of Oncological Sciences · doi:10.1016/j.jons.2017.04.001 · Cited by 111
Tumor location impacts immune response in mouse models of colon cancer
Zhao, X., Li, L., Starr, T. K., & Subramanian, S. (2017) · Oncotarget · doi:10.18632/oncotarget.18423 · Cited by 111
Garant, A., Guilbault, C., Ekmekjian, T., Greenwald, Z. R., Murgoi, P., & Vuong, T. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.10.009 · Cited by 111
Li, X., Wang, X., Ito, A., & Tsuji, N. M. (2020) · Nature Communications · doi:10.1038/s41467-020-17637-z · Cited by 111
Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options
Kohoutová, D., Worku, D. A., Aziz, H., TEARE, J. P., Weir, J., & Larkin, J. (2021) · Cells · doi:10.3390/cells10020327 · Cited by 111
Self-citationTong, H., Sun, J., Fang, J., Zhang, M., Liu, H., Xia, R., Zhou, W., Liu, K., & Chen, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859323 · Cited by 111
Zhang, Z., Xu, X., Du, J., Chen, X., Xue, Y., Zhang, J., Yang, X., Chen, X. S., Xie, J., & Ju, S. (2024) · Nature Communications · doi:10.1038/s41467-024-44963-3 · Cited by 111
Immuno-oncology combinations: raising the tail of the survival curve
Harris, S. J., Harris, S. J., Brown, J. S., Lopez, J. S., Yap, T. A., Brown, J. S., Lopez, J. S., & Yap, T. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0015 · Cited by 110
The network of immunosuppressive pathways in glioblastoma
Mangani, D., Weller, M., & Roth, P. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.011 · Cited by 110
Cost-Effectiveness of Immune Checkpoint Inhibition inBRAFWild-Type Advanced Melanoma
Kohn, C. G., Zeichner, S. B., Chen, Q., Montero, A. J., Goldstein, D. A., & Flowers, C. R. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.6336 · Cited by 110
The use of immunotherapy in the treatment of melanoma
Achkar, T., & Tarhini, A. A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0458-3 · Cited by 110
Toxicities Associated With PD-1/PD-L1 Blockade
Wang, D. Y., Johnson, D. B., & Davis, E. J. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000296 · Cited by 110
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
Onoyama, T., Takeda, Y., Yamashita, T., Hamamoto, W., Sakamoto, Y., Koda, H., Kawata, S., Matsumoto, K., & Isomoto, H. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i3.353 · Cited by 110
Ugurel, S., Schadendorf, D., Horny, K., Sucker, A., Schramm, S., Utikal, J. S., Pföhler, C., Herbst, R. A., Schilling, B., Blank, C. U., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.09.005 · Cited by 110
Self-citationHuffman, B. M., Kottschade, L. A., Kamath, P. S., & Markovic, S. N. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000374 · Cited by 100
Khoja, L., Maurice, C., Chappell, M., MacMillan, L., Al-Habeeb, A. S., Al-Faraidy, N., Butler, M. O., Rogalla, P., Mason, W., Joshua, A. M., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0186 · Cited by 109
Zhu, Z., Liu, W., & Gotlieb, V. K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.002 · Cited by 109
Combinatorial approach to cancer immunotherapy: strength in numbers
Vilgelm, A. E., Johnson, D. B., & Richmond, A. J. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 109
Alva, A. S., Daniels, G. A., Wong, M. K., Kaufman, H. L., Morse, M. A., McDermott, D. F., Clark, J. I., Agarwala, S. S., Miletello, G. P., Logan, T. F., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1910-x · Cited by 109
The emerging role of immune checkpoint inhibition in malignant lymphoma
Hude, I., Sasse, S., Engert, A., & Bröckelmann, P. J. (2016) · Haematologica · doi:10.3324/haematol.2016.150656 · Cited by 109
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Astaras, C., Micheli, R. D., Moura, B. G., Hundsberger, T., & Hottinger, A. F. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0810-1 · Cited by 109
TIGIT, a novel immune checkpoint therapy for melanoma
Tang, W., Chen, J., Ji, T., & Cong, X. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05961-3 · Cited by 109
Wistuba-Hamprecht, K., Martens, A., Heubach, F., Romano, E., Geukes Foppen, M., Yuan, J., Postow, M., Wong, P., Mallardo, D., Schilling, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.011 · Cited by 108
Self-citationChallenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
Postel-Vinay, S. C., Aspeslagh, S., Lanoy, É., Robert, C., Soria, J., & Marabelle, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv550 · Cited by 108
Self-citationAutoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors
Tocut, M., Brenner, R. M., & Zandman‐Goddard, G. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.010 · Cited by 108
Targeting DNA repair in cancer: current state and novel approaches
Klinakis, A., Karagiannis, D., & Rampias, T. N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03299-8 · Cited by 108
Shah, A. N., Flaum, L., Helenowski, I., Santa-Maria, C. A., Jain, S., RADEMAKER, A. W., Nelson, V. M., Tsarwhas, D., Cristofanilli, M., & Gradishar, W. J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000173 · Cited by 108
T-cell-based immunotherapy in colorectal cancer
Feng, M., Zhao, Z., Yang, M., Ji, J., & Zhu, D. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.040 · Cited by 108
Yang, Y. P., Xu, J., Sun, Y., Mo, L., Liu, B., Pan, X., Liu, Z., & Tan, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c02016 · Cited by 108
Bai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107
Autoimmune endocrine dysfunctions associated with cancer immunotherapies
Ferrari, S. M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M. R., Baldini, E., Ulisse, S., Marone, G., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102560 · Cited by 107
Ocular toxicities of MEK inhibitors and other targeted therapies
Stjepanovic, N., Velazquez-Martin, J. P., & Bedard, P. L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw100 · Cited by 107
Jochems, A., Schouwenburg, M. G., Leeneman, B., Franken, M. G., van den Eertwegh, A. J. M., Haanen, J. B. A. G., Gelderblom, H. A. J., Groot, C. A. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.11.021 · Cited by 107
Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges
Diesendruck, Y., & Benhar, I. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.001 · Cited by 107
Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review
Heppt, M. V., Steeb, T., Schlager, J. G., Rosumeck, S., Dressler, C., Ruzicka, T., Nast, A., & Berking, C. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.009 · Cited by 107
Feng, S., Coward, J. I. G., McCaffrey, E., Coucher, J., Kalokerinos, P. N., & O'Byrne, K. J. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.007 · Cited by 107
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings
Wang, G. X., Kurra, V., Gainor, J. F., Sullivan, R. J., Flaherty, K. T., Lee, S. I., & Fintelmann, F. J. (2017) · Radiographics · doi:10.1148/rg.2017170085 · Cited by 107
McEvoy, A. C., Warburton, L., Al‐Ogaili, Z., Celliers, L., Calapre, L., Pereira, M. R., Khattak, M. A., Meniawy, T. M., Millward, M., Ziman, M. R., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4637-6 · Cited by 107
Petrelli, F., Ardito, R., Borgonovo, K., Lonati, V., Cabiddu, M., Ghilardi, M., & Barni, S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.129 · Cited by 107
Jiang, K., Li, J., Zhang, J., Wang, L., Zhang, Q., Ge, J., Guo, Y., Wang, B., Huang, Y., Yang, T., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105818 · Cited by 107
Cutaneous melanoma and the immunotherapy revolution (Review)
Leonardi, G. C., Candido, S., Falzone, L., Spandidos, D. A., & Libra, M. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5088 · Cited by 107
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
Marletta, S., Fusco, N., Munari, E., Luchini, C., Cimadamore, A., Brunelli, M., Querzoli, G., Martini, M., Vigliar, E., Colombari, R., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071073 · Cited by 107
Immune‐Related Adverse Events From Immune Checkpoint Inhibitors
Marrone, K. A., Ying, W., & Naidoo, J. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.394 · Cited by 106
Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review
Jhaveri, K. D., Wanchoo, R., Sakhiya, V., Ross, D. W., & Fishbane, S. N. (2016) · Kidney International Reports · doi:10.1016/j.ekir.2016.09.055 · Cited by 106
Haddox, C. L., Shenoy, N. K., Shah, K., Kao, J. C., Jain, S., Halfdanarson, T. R., Wijdicks, E. F. M., & Goetz, M. P. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw655 · Cited by 106
Choong, E. S., Lo, S., Drummond, M., Fogarty, G. B., Menzies, A. M., Guminski, A. D., Shivalingam, B., Clarke, K., Long, G. V., & Hong, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.007 · Cited by 106
Self-citationHao, C., Tian, J., Liu, H., Li, F., Niu, H., & Zhu, B. (2017) · Medicine · doi:10.1097/md.0000000000007325 · Cited by 106
Immune cell profiling in cancer: molecular approaches to cell-specific identification
Lyons, Y. A., Wu, S. Y., Overwijk, W. W., Baggerly, K., & Sood, A. K. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0031-0 · Cited by 106
Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management
Grover, S., Rahma, O. E., Hashemi, N., & Lim, R. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100013 · Cited by 106
Cardiorenal complications of immune checkpoint inhibitors
Sury, K., Perazella, M. A., & Shirali, A. C. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0035-1 · Cited by 106
Dahal, U., Le, K., & Gupta, M. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000580 · Cited by 106
Wan, X., Luo, X., Tan, C., Zeng, X., Zhang, Y., & Peng, L. (2019) · Cancer · doi:10.1002/cncr.32368 · Cited by 106
Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives
Weenink, B., French, P. J., Smitt, P. A. E. S., Debets, R., & Geurts, M. (2020) · Cancers · doi:10.3390/cancers12030751 · Cited by 106
Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy
Sun, X., Zhang, N., Yin, C., Zhu, B., & Li, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00951 · Cited by 106
Donia, M., Kimper-Karl, M. L., Høyer, K. L., Bastholt, L., Schmidt, H., & Svane, I. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.017 · Cited by 105
Lomax, A. J., McGuire, H. M., McNeil, C. M., Choi, C. J., Hersey, P., Karikios, D. J., Shannon, K. F., van Hal, S., Carr, U., Crotty, A., et al. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13076 · Cited by 105
Self-citationEfficacy of anti-PD-1 therapy in patients with melanoma brain metastases
Parakh, S., Park, J., Mendis, S. R., Rai, R., Xu, W., Lo, S., Drummond, M., Rowe, C. E., Wong, A. N. M., McArthur, G. A., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.142 · Cited by 105
Self-citationLimitations and opportunities for immune checkpoint inhibitors in pediatric malignancies
Park, J. A., & Cheung, N. V. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.006 · Cited by 105
Scleroderma Induced by Pembrolizumab: A Case Series
Barbosa, N. S., Wetter, D. A., Wieland, C. N., Shenoy, N. K., Markovic, S. N., & Thanarajasingam, U. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.03.016 · Cited by 105
Epigenetic modifiers as new immunomodulatory therapies in solid tumours
Aspeslagh, S., Morel, D., Soria, J., & Postel-Vinay, S. C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy050 · Cited by 105
Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion
DeVito, N. C., Plebanek, M. P., Theivanthiran, B., & Hanks, B. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02876 · Cited by 105
Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
Robert, C., Marabelle, A., Herrscher, H., Caramella, C., Rouby, P., Fizazi, K. S., & Besse, B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0399-6 · Cited by 105
Self-citationHuang, W., Jiang, Y., Xiong, W., Sun, Z., Chen, C., Yuan, Q., Zhou, K., Han, Z., Feng, H., Chen, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32816-w · Cited by 105
Xi, L., Pham, T. H.-T., Payabyab, E. C., Sherry, R. M., Rosenberg, S. A., & Raffeld, M. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0613 · Cited by 104
Harrington, K. J., Andtbacka, R. H. I., Collichio, F. A., Downey, G. F., Chen, L., Szabó, Z. R., & Kaufman, H. L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s115245 · Cited by 104
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
Varricchi, G., Loffredo, S., Marone, G., Modestino, L., Fallahi, P., Ferrari, S. M., de Paulis, A., Antonelli, A., & Galdiero, M. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163934 · Cited by 104
Harnessing cancer immunotherapy during the unexploited immediate perioperative period
Matzner, P., Sandbank, E., Neeman, E., Zmora, O., Gottumukkala, V. N. R., & Ben‐Eliyahu, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0319-9 · Cited by 104
Robert, C., Hwu, W., Hamid, O., Ribas, A., Weber, J. S., DAUD, A. I., Hodi, F. S., Wolchok, J. D., Mitchell, T. C., Hersey, P., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.010 · Cited by 104
Self-citationEnhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
Curti, B. D., Koguchi, Y., Leidner, R. S., Rolig, A. S., Sturgill, E. R., Sun, Z., Wu, Y., Rajamanickam, V., Bernard, B. M., Hilgart-Martiszus, I., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002371 · Cited by 104
Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors
Blumenthal, D. T., Yalon, M., Vainer, G. W., Lossos, A., Yust, S., Lior, T., Cagnano, E., Limon, D., & Bokstein, F. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2190-1 · Cited by 104
An Update on Immunotherapy for Solid Tumors: A Review
Pham, T. D., Roth, S., Kong, J. C. H., Guerra, G., Narasimhan, V., Pereira, L. A., Desai, J., Heriot, A. G., & Ramsay, R. G. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6658-4 · Cited by 104
Rose, A. A. N., Biondini, M., Curiel, R. E., & Siegel, P. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.010 · Cited by 103
Recent developments with immunotherapy for hepatocellular carcinoma
Waidmann, O. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1499722 · Cited by 103
Chen, Y., Pei, Y., Luo, J., Huang, Z., Yu, J., & Meng, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01088 · Cited by 103
Chesney, J. A., Puzanov, I. J., Collichio, F. A., Singh, P. P., Milhem, M. M., Glaspy, J. A., Hamid, O., Ross, M. I., Friedlander, P. A., Garbe, C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006270 · Cited by 103
Self-citationGogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.004 · Cited by 102
Self-citationPolyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma
Paepegaey, A.-C., Lheure, C., Ratour, C., Lethielleux, G., Clerc, J., Bertherat, J., Kramkimel, N., & Groussin, L. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00170 · Cited by 102
Evolving treatment options for melanoma brain metastases
Ajithkumar, T., Parkinson, C., Fife, K. M., Corrie, P. G., & Jefferies, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00141-2 · Cited by 102
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient
Herz, S., Höfer, T., Papapanagiotou, M., Leyh, J., Meyenburg, S., Schadendorf, D., Ugurel, S., Roesch, A., Livingstone, E., Schilling, B., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.026 · Cited by 102
Talimogene Laherparepvec: Review of its Mechanism of Action and Clinical Efficacy and Safety
Raman, S. S., Hecht, J. R., & Chan, E. (2019) · Immunotherapy · doi:10.2217/imt-2019-0033 · Cited by 102
Sha, C. M., Lehrer, E. J., Hwang, C., Trifiletti, D. M., Mackley, H. B., Drabick, J. J., & Zaorsky, N. G. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.07.035 · Cited by 102
Deshpande, R. P., Sharma, S., & Watabe, K. (2020) · Cancers · doi:10.3390/cancers12102983 · Cited by 102
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC
Welsh, J. W., Heymach, J. V., Guo, C., Menon, H., Klein, K., Cushman, T. R., Verma, V., Hess, K. R., Shroff, G., Tang, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.08.022 · Cited by 101
Bilen, M. A., Subudhi, S. K., Gao, J., Tannir, N. M., Tu, S., & Sharma, P. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0139-8 · Cited by 101
Nivolumab-associated acute glomerulonephritis: a case report and literature review
Jung, K., Zeng, X., & Bilušić, M. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0408-2 · Cited by 101
Cho, H., Kang, H., Lee, H., & Kim, C. W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071517 · Cited by 101
Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes
Colunga, A., Pulliam, T. H., & Nghiem, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0439 · Cited by 101
Carlino, M. S., Long, G. V., Schadendorf, D., Robert, C., Ribas, A., Richtig, E., Nyakas, M., Caglevic, C., Tarhini, A., Blank, C. U., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.034 · Cited by 101
Self-citationPerez, M. C., Miura, J. T., Naqvi, S. M. H., Kim, Y., Holstein, A. H., Lee, D. H., Sarnaik, A. A., & Zager, J. S. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6803-0 · Cited by 101
Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100
Sridharan, V., Gjini, E., Liao, X., Chau, N. G., Haddad, R. I., Severgnini, M., Hammerman, P. S., El‐Naggar, A. K., Freeman, G. J., Hodi, F. S., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0031 · Cited by 100
Metadata
- Authors
- Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C. U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N., Ebbinghaus, S., & Ribas, A.
- Affiliations
- Université Paris-Sud (FR)
- Sheba Medical Center (IL)
- Hospital Clínic de Barcelona (ES)
- Hôpital de la Timone (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- University of California, San Francisco (US)
- Royal Prince Alfred Hospital (AU)
- Hadassah Medical Center (IL)
- Royal Marsden Hospital (GB)
- University of Manchester (GB)
- Universitair Ziekenhuis Brussel (BE)
- The Netherlands Cancer Institute (NL)
- Angeles Clinic and Research Institute (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2521-2532
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152897456
- Semantic Scholar
- 0dac3ea80083f0a86598cb9af0a205554280551b
- Cited by
- 5,887
- References
- 26
- Citations by year
- 2026: 234 · 2025: 298 · 2024: 374 · 2023: 421 · 2022: 471 · 2021: 568 · 2020: 659 · 2019: 585 · 2018: 684 · 2017: 761 · 2016: 628 · 2015: 188
- FWCI
- 329.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Genentech
- Kite Pharma
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- ipilimumab, advanced melanoma, immune checkpoint inhibitors, anti-PD-1 therapy, CTLA-4 inhibition, progression-free survival, overall survival, dosing frequency, treatment-related adverse events, immune-related adverse events, response rate
- MeSH terms
- Ipilimumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Analysis, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
